Are the favorable cardiovascular outcomes of empagliflozin treatment explained by its effects on multiple cardiometabolic risk factors? A simulation of the results of the EMPA-REG OUTCOME trial
Reports
Co-morbid conditions and complications,
Data analysis methods,
Medication management
Data analysis methods,
Medication management
